drugset / Trial / NCT02249338

Effect of BIIL 284 BS on Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT02249338

Phase 2 Completed 53 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Study to investigate the effect of 14-day treatment with BIIL 284 BS on sputum neutrophils and specific inflammatory markers in patients with clinically well-defined moderate chronic obstructive pulmonary disease (COPD)

Timeline

Start
1999-10
Primary completion
2000-04
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject AMELUBANT Small molecule